Table 2.
Tumour subclones for survival analysis in the genomic development dataset.
| Genomic subclone | HR (95% CI) | Log-rank p | Corrected p | 
|---|---|---|---|
| Cell cycle | 1.574 (1.045–2.371) | 0.037 | 0.099 | 
| Alzheimer’s disease | 1.507 (0.978–2.321) | 0.085 | 0.170 | 
| Peroxisome | 1.374 (0.834–2.265) | 0.257 | 0.300 | 
| ECM-receptor interaction | 1.303 (0.785–2.163) | 0.268 | 0.300 | 
| Cholinergic synapse | 0.751 (0.467–1.206) | 0.272 | 0.300 | 
| Primary immunodeficiency | 0.519 (0.343–0.784) | 0.004 | 0.016 | 
| Protein digestion and absorption | 1.249 (0.807–1.934) | 0.300 | 0.300 | 
| Consensus Cluster | 1.993 (1.327–2.994) | 0.0012 | 0.010 | 
Statistical significance was assessed by the two-sided log-rank test.
p values were adjusted for multiple comparisons.
HR hazard ratio.